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1  | INTRODUC TION
Infections due to Mycoplasma pneumoniae occur both endemically 
and epidemically worldwide and are one of the most common bac-
terial causes of pneumonia. Resistance to macrolides, traditionally 
the treatment of choice, emerged in Japan in 2001. Subsequently, 
macrolide resistance spread throughout East Asia, with >80% of 
isolates in China resistant by 2006. In Europe, prevalence is sub-
stantially lower than in Asia and varies from country to country, 
with recent reports ranging from very low levels of 1% in Slovenia 
and 1.6% in Denmark to 3.6% in Germany, 9.8% in France, 19% in 
the United Kingdom, 26% in Italy, and 30% in Israel.1 In the United 
States, Waites et al collected 360 clinical specimens from hospi-
tals in 8 states between 2015 and 2018 and found 7.5% of iso-
lates to be resistant. However, resistance varied geographically, 
ranging from <2% in the west to more than 20% in the southeast 
and northeast. 33.3% of patients with macrolide resistance had a 
history of immune deficiency or malignancy.2 Importantly, resis-
tance appears to reasonably correlate with outcome, with defer-
vescence of fever within 48 hours seen in 77%-85% of patients 
receiving fluoroquinolones or minocycline versus only 28% in pa-
tients receiving macrolides.3 Despite this compelling data, macro-
lide-resistant M pneumoniae (MRMP) may be under-appreciated as 
a threat for several reasons. First, M pneumoniae generally causes 
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Abstract
Mycoplasma pneumoniae is one of the most common bacterial causes of pneumo-
nia. Macrolide-resistant M pneumoniae (MRMP) was documented in 7.5% of isolates 
in the United States. Resistance portends poor outcomes to macrolide therapy, yet 
patients respond well to fluoroquinolones or tetracyclines such as minocycline. 
However, MRMP may be under-appreciated because M pneumoniae generally causes 
relatively mild infections in non-immunosuppressed adults that may resolve without 
effective therapy and because microbiological confirmation and susceptibility are not 
routinely performed. We report two cases of pneumonia due to MRMP in kidney 
transplant recipients. Both patients required hospital admission, worsened on mac-
rolide therapy, and rapidly defervesced on doxycycline or levofloxacin. In one case, 
M pneumoniae was only identified by multiplex respiratory pathogen panel analysis 
of BAL fluid. Macrolide resistance was confirmed in both cases by real-time PCR and 
point mutations associated with macrolide resistance were identified. M pneumoniae 
was isolated from both cases, and molecular genotyping revealed the same genotype. 
In conclusion, clinicians should be aware of the potential for macrolide resistance in 
M pneumoniae, and may consider non-macrolide-based therapy for confirmed or non-
responding infections in patients who are immunocompromised or hospitalized.
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relatively mild infections in healthy patients that may resolve 
even with ineffective therapy. In addition, M pneumoniae micro-
biological diagnosis and susceptibility testing are not routinely 
performed.2
In January 2018, a 23-year-old man with a history of autism 
spectrum disorder, developmental delay, and epilepsy was ad-
mitted to Michigan Medicine with necrotizing pneumonia com-
plicated by acute respiratory distress syndrome (ARDS) requiring 
extracorporeal membrane oxygenation (ECMO). Broad-spectrum 
antimicrobial therapy, consisting of intravenous (IV) vancomycin, 
tobramycin, piperacillin-tazobactam, and azithromycin (500 mg 
daily), was initiated. A multipathogen nucleic acid amplifica-
tion test for respiratory pathogens (RPAN) (BioFire® FilmArray® 
Respiratory Panel, BioFire Diagnostics) was positive for only 
M pneumoniae, and a bronchoalveolar lavage (BAL) performed the 
same day noted purulent secretions but yielded no growth on rou-
tine bacterial culture. After 7 days of therapy with azithromycin, 
given the severity of infection and knowledge of the possibility 
for MRMP, levofloxacin 750 mg IV daily was added at the recom-
mendation of the infectious diseases service. The BAL sample was 
sent to the Diagnostic Mycoplasma Laboratory at the University 
of Alabama at Birmingham (UAB) for detection of macrolide re-
sistance. He was extubated after 4 days of levofloxacin therapy, 
completed a 14-day course of levofloxacin, and transferred to in-
patient rehabilitation. Molecular testing performed directly on the 
BAL specimen confirmed macrolide resistance.3,4
Given the above case, we were alert to the possibility of MRMP. 
Recently, we cared for two immunocompromised patients—with no 
known contact with each other—who presented within 1 week of 
each other with pneumonia due to M pneumoniae that failed mac-
rolide therapy and responded to alternative antimicrobials. As such, 
we wish to raise the awareness of MRMP with clinicians, especially 
in immunocompromised patients.
The University of Michigan Investigational Review Board granted 
exempt status for this study.
2  | C A SE 1
In January 2020, a 30-year-old woman presented to Michigan 
Medicine complaining of abdominal pain, nausea, vomiting, and 
fever. She had a history of end-stage renal disease due to re-
flux nephropathy and underwent kidney transplantation in 2005 
(complicated by rejection), and a second transplant in 2012. Her 
maintenance immunosuppression consisted of mycophenolic acid 
540 mg twice daily, prednisone 5 mg once daily, and tacrolimus 
(5 mg every morning and 4 mg every evening). She also had a his-
tory of B-cell lymphoma in 2006 that was in remission. On ad-
mission, she did not endorse cough or dyspnea, and a chest x-ray 
was unremarkable. A nasopharyngeal RPAN was positive for only 
M pneumoniae. She completed 5 days of azithromycin (500 mg IV 
X 1 followed by 250 mg IV daily X 4 days), improved, and was dis-
charged. Five days after discharge, she reported productive cough, 
dyspnea, sputum production, fevers, chills, nausea, vomiting, and 
abdominal pain. After 3 days of these symptoms (8 days after her 
discharge), she returned to our emergency department. She was 
febrile to 38.9°C and a CT scan showed extensive multifocal pneu-
monia. RPAN was again positive for only M pneumoniae. Sputum 
culture indicated the presence of oropharyngeal commensal flora. 
She was started on IV vancomycin, piperacillin-tazobactam, and 
doxycycline (100 mg twice daily), and her fever defervesced within 
24 hours. Transplant infectious diseases were consulted, and her 
antimicrobials were replaced by levofloxacin 750 mg IV every 
48 hours (renally adjusted dose). Her nasopharyneal sample was 
sent to the UAB Diagnostic Mycoplasma Laboratory which identi-
fied MRMP. She was discharged 4 days after admission to com-
plete a 10-day course of oral levofloxacin 750 mg every 48 hours. 
She was seen at Nephrology Transplant Clinic 12 days later and 
denied diarrhea, fever, or cough.
3  | C A SE 2
In January 2020, a 39-year-old woman presented to Michigan 
Medicine with cough, shortness of breath, fevers, chills, nausea, and 
vomiting. She had a history of Hirschsprung disease, cloacal atresia 
status post-multiple surgeries, end-stage renal disease with a kid-
ney transplant in 2013, and Epstein-Barr virus (EBV)-related spindle 
cell tumor of the liver in 2017. Her maintenance immunosuppression 
consisted of prednisone 10 mg daily and tacrolimus 0.5 mg twice 
daily. In December of 2019, she received 3 weekly doses of HLA re-
stricted EBV-directed cytotoxic T cells to treat her EBV-related ma-
lignancy. Upon presentation in the emergency department, she was 
febrile to 39.3°C and a chest x-ray demonstrated a right upper lobe 
pneumonia. A nasopharyngeal RPAN was negative. She was started 
on piperacillin-tazobactam, vancomycin, oral azithromycin (500 mg 
X 1 followed by 250 mg daily) and admitted. Her therapy was tran-
siently de-escalated to ampicillin-sulbactam and azithromycin, but 
was quickly broadened back to piperacillin-tazobactam, vancomycin, 
and azithromycin given continued fevers. A sputum culture resulted 
as oropharyngeal commensal flora. Given continued cough, short-
ness of breath, and fevers, a chest CT was ordered on day 5 of hos-
pitalization and demonstrated multiple patchy consolidations and 
centrilobular nodules involving the right lung (Figure 1). Transplant 
infectious diseases were subsequently consulted and recommended 
continuation of piperacillin-tazobactam. She continued to have fe-
vers (39.3°C on day 7 of hospitalization), and a bronchoscopy with 
BAL was performed on day 7. The BAL grew mixed oral flora and 
rare Candida albicans, but a RPAN performed on the BAL fluid was 
positive for only M pneumoniae. A BAL sample was sent to the UAB 
Diagnostic Mycoplasma Laboratory and identified MRMP. On day 
8 of hospitalization, oral levofloxacin 750 mg daily was added and 
her fevers defervesced. She was discharged on day 10 to complete 
a 10-day course of levofloxacin. She was seen in infectious diseases 
clinic 7 days after discharge and was improving with resolution of 
cough and fever.
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3.1 | Mycoplasma laboratory testing
3.1.1 | Mycoplasma pneumoniae PCR and culture
DNA was isolated from the original nasopharyngeal and BAL sam-
ples and tested by real-time PCR assays on a Roche LightCycler 480 
(Roche Diagnostics) to detect M pneumoniae and the point mutations 
in 23S rRNA gene known to be associated with macrolide resistance 
in M pneumoniae.1,5 Specimens were also cultured successfully from 
both specimens using SP4 broth and agar to obtain M pneumoniae 
isolates.6
3.1.2 | Molecular genotyping
Both P1 subtyping and multi-locus variable tandem repeat analy-
sis (MLVA) were performed on the two M pneumoniae isolates. 
Conventional PCRs were used to amplify the P1 gene and the tan-
dem repeat fragments. Two portions of the P1 gene were amplified 
using primer pairs ADH1/ADH27 and Mp5f/M16r.8 The 4-locus 
MLVA typing scheme (Mpn 13-16) was used as described.9 PCR was 
carried out on a Veriti 96-well thermal cycler (Applied Biosystems) 
with a 25 μL PCR reaction volume containing 0.4 μmol/L of each 
primer, 2.5 μL of 10X AccuPrime Pfx reaction mix (Thermo Fisher), 
0.5 U of AccuPrime Pfx DNA polymerase, and 2 μL of template 
DNA. Amplicons were sequenced by Sanger sequencing at the UAB 
Heflin Genomics Center and analyzed using CLC Main Workbench 
12 (Qiagen). The amplicons from the real-time PCR detecting the 
23S rRNA mutations were sequenced as well. The assembled se-
quences were compared with the reference sequences in NCBI, 
and both isolates were identified to be P1 subtype 2 (P1-2) variant 
2c and MLVA type 3-5-6-2. The isolate from case 1 carried a point 
mutation A2063G (M pneumoniae numbering) in 23S rRNA gene, 
while A2064G was found in case 2.
4  | DISCUSSION
We report two cases in solid organ transplant patients illustrating 
the clinical impact of infection due to MRMP. These cases also rep-
resent, to our knowledge, the first cases of MRMP in the state of 
Michigan. There are several interesting characteristics of our expe-
rience. First, both patients were clearly failing macrolide therapy, 
as manifested by continued high fevers. However, the response to 
alternative therapy was dramatic, with a resolution of fevers within 
24 hours of converting to doxycycline and levofloxacin, respectively. 
Although quinolone therapy represented the definitive therapy in 
our patients, adult10 and pediatric11 data from Japan confirm that tet-
racyclines such as minocycline are also efficacious for the treatment 
of macrolide-resistant M pneumoniae pneumonia. Our second case is 
also notable in that although the patient had a negative RPAN from a 
retropharyngeal swab on admission, RPAN testing was subsequently 
positive for M pneumoniae from a BAL sample. There are several pos-
sible explanations for this, including inadequate collection of the na-
sopharyngeal specimen, but in this case, deep respiratory sampling 
was necessary to procure a diagnosis and identification of optimal 
therapy. There is some evidence to suggest that lower respiratory 
specimens such as sputum and BAL may contain larger numbers of 
organisms making it easier for them to be detected.1
The M pneumoniae isolates from both cases have the same gen-
otypes: P1-2 variant 2c and MLVA type 3-5-6-2. However, this does 
not necessarily mean that there was transmission from one patient 
to another. First, these genotypes are the most common types 
identified in a recent surveillance in 9 locations across the United 
States.2,12 Although Michigan was not included in the surveillance, 
we expect the general strain type distribution to be similar to other 
geographic areas and it is certainly possible both patients could have 
independently acquired the same strain from different sources. 
Second, the macrolide-resistant point mutations in the two isolates 
are different, suggesting different evolving routes for resistance 
development.
Diagnosis of M pneumoniae infection was achieved by PCR, now 
the diagnostic method of choice.1 Serologic testing was used for 
many years prior to the availability of molecular methods, despite 
significant shortcomings and the likelihood for both false-positive 
and false-negative results. Serum samples taken during the acute 
phase of illness may not be indicative of current infection, either 
because it is too soon for antibody detection or because some indi-
viduals have persistently elevated antibodies. In addition, IgM may 
not be produced during reinfection in persons older than 40 years. 
Serology is unreliable in immunosuppressed persons who may be 
unable to mount a humoral immune response, whether it is innate or 
iatrogenic, so it was not a consideration in the present cases.1
In conclusion, clinicians should be aware of the potential for 
macrolide resistance in M pneumoniae and should maintain a high 
F I G U R E  1   Computed Tomography of the chest of Case 2
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index of suspicion in patients who fail to defervesce promptly on 
macrolide therapy. As a result of our experience, we no longer treat 
immunocompromised patients with M pneumoniae pneumonia with 
macrolides. Continued vigilance and surveillance are necessary to 
track the evolving epidemiology of MRMP.
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